Evaluating the Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube.

IF 3.8 4区医学 Q2 IMMUNOLOGY

Open Forum Infectious Diseases Pub Date : 2025-09-24 eCollection Date: 2025-10-01 DOI:10.1093/ofid/ofaf588

Joshua Mercure, Kayla Bey, Eric Gillett, Jeffrey C Pearson, Suzanne M McCluskey, Alex E Rock

引用次数: 0

Abstract

Human immunodeficiency virus (HIV) viral suppression was evaluated after receipt of crushed or dissolved bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered via enteral tube during hospitalization. Eighty-nine percent of patients (17/19) were virally suppressed (<200 copies/mL) within 1 year of receiving B/F/TAF via tube, suggesting that administration via tube is a reasonable alternative to changing antiretroviral regimens.

查看原文本刊更多论文

比替格拉韦/恩曲他滨/替诺福韦阿拉那胺粉碎管给药的疗效评价。

在住院期间通过肠内管接受粉碎或溶解的比替格拉韦/恩曲他滨/替诺福韦·阿拉法胺（B/F/TAF）后，评估人类免疫缺陷病毒（HIV）病毒抑制情况。89%的患者（17/19）病毒被抑制(

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.